Biotron Limited (ASX:BIT)
Australia · Delayed Price · Currency is AUD 0.0025
0.00 (0.00%)
At close: Mar 27, 2026
Biotron Revenue
Biotron had revenue of -868.00 AUD in the twelve months ending December 31, 2025. In the fiscal year ending June 30, 2025, Biotron had annual revenue of 1.81M with 10.24% growth.
Revenue (ttm)
-868.00
Revenue Growth
+10.24%
P/S Ratio
-7,781.87
Revenue / Employee
-289.33
Employees
3
Market Cap
6.75M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Jun 30, 2025 | 1.81M | 168.51K | 10.24% |
| Jun 30, 2024 | 1.65M | 213.83K | 14.94% |
| Jun 30, 2023 | 1.43M | -127.24K | -8.16% |
| Jun 30, 2022 | 1.56M | 96.58K | 6.61% |
| Jun 30, 2021 | 1.46M | 658.92K | 82.05% |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Chimeric Therapeutics | 9.75M |
| Immuron | 7.48M |
| Tissue Repair | 3.38M |
| Acrux | 2.81M |
| Nexalis Therapeutics | 761.96K |
| AdAlta | 608.07K |
| Bio-Gene Technology | 390.63K |
| Invex Therapeutics | 229.08K |